These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 29574225

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK.
    Huang Q, Wang T, Yang L, Wang HY.
    Int J Mol Sci; 2017 May 19; 18(5):. PubMed ID: 28534819
    [Abstract] [Full Text] [Related]

  • 4. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK, Dai W, Zheng YW, Zhao SP.
    Mol Med; 2019 Jun 13; 25(1):26. PubMed ID: 31195981
    [Abstract] [Full Text] [Related]

  • 5. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    Fang K, Wu F, Chen G, Dong H, Li J, Zhao Y, Xu L, Zou X, Lu F.
    BMC Complement Altern Med; 2019 Sep 13; 19(1):255. PubMed ID: 31519174
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
    Pyun DH, Kim TJ, Park SY, Lee HJ, Abd El-Aty AM, Jeong JH, Jung TW.
    Mol Cell Endocrinol; 2021 Dec 01; 538():111464. PubMed ID: 34601002
    [Abstract] [Full Text] [Related]

  • 9. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S, Soares E Silva A, Gomes F, Ribeiro E, Oliveira W, Oliveira A, Lima I, Lima MDC, Pitta I, Peixoto C.
    Eur J Pharmacol; 2016 Oct 05; 788():306-314. PubMed ID: 27349145
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathway.
    Meng D, Yin G, Chen S, Zhang X, Yu W, Wang L, Liu H, Jiang W, Sun Y, Zhang F.
    Eur J Pharmacol; 2024 Aug 15; 977():176737. PubMed ID: 38866362
    [Abstract] [Full Text] [Related]

  • 12. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
    Liu Y, Li Y, Wang J, Yang L, Yu X, Huang P, Song H, Zheng P.
    BMC Complement Med Ther; 2022 Aug 09; 22(1):213. PubMed ID: 35945571
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway.
    Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH.
    World J Gastroenterol; 2019 Dec 07; 25(45):6607-6618. PubMed ID: 31832001
    [Abstract] [Full Text] [Related]

  • 15. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
    Xu N, Luo H, Li M, Wu J, Wu X, Chen L, Gan Y, Guan F, Li M, Su Z, Chen J, Liu Y.
    Biomed Pharmacother; 2021 Feb 07; 134():111104. PubMed ID: 33341045
    [Abstract] [Full Text] [Related]

  • 16. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, Chang KC.
    Eur J Pharmacol; 2016 Oct 05; 788():200-209. PubMed ID: 27343380
    [Abstract] [Full Text] [Related]

  • 17. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X, Xu L, Zhang M, Zhang P, Wang Y, Wang Y, Zhao Z, Chen H, Liu X, Zhang Y.
    Biochem Biophys Res Commun; 2016 Apr 15; 472(4):603-9. PubMed ID: 26970305
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
    Li Q, Tan JX, He Y, Bai F, Li SW, Hou YW, Ji LS, Gao YT, Zhang X, Zhou ZH, Yu Z, Fang M, Gao YQ, Li M.
    Int J Biol Sci; 2022 Apr 15; 18(4):1594-1611. PubMed ID: 35280674
    [Abstract] [Full Text] [Related]

  • 20. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
    Liou CJ, Lee YK, Ting NC, Chen YL, Shen SC, Wu SJ, Huang WC.
    Cells; 2019 May 11; 8(5):. PubMed ID: 31083505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.